Discontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation

Discontinuation for Oral Anticoagulants During the First Year of Use in Patients With Atrial Fibrillation Covered by a Medical Insurance

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04133545

Enrollment

360

Registered

2019-10-21

Start date

2018-04-04

Completion date

2020-09-30

Last updated

2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anticoagulant Drugs, Auricular Fibrillation

Brief summary

The purpose of this study is to compare the discontinuation rates for vitamin K antagonists and for direct oral anticoagulants during their first year

Detailed description

The purpose of this study is to compare the discontinuation rates for vitamin K antagonists and for direct oral anticoagulants during their first year of use after their initiation during hospitalization in patients covered by our health insurance plan.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patient older than 18 years of age covered by our Health Care Insurance Plan. 2. Indication for oral anticoagulation with an expected duration of use of no less than 1 year.

Exclusion criteria

1. Refusal to take part. 2. Use of oral anticoagulants within 6 months prior to admission. 3. Presence of mechanical prosthetic valve. 4. Chronic renal failure with creatinine clearance \<30 mL/min (estimated using the MDRD formula).

Design outcomes

Primary

Measure	Time frame	Description
Anticoagulant Discontinuation Rate	One year	Anticoagulant Discontinuation Rate

Secondary

Measure	Time frame	Description
Discontinuation Predictors	One year	Discontinuation Predictors

Countries

Argentina

Outcome results